Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Germ Cell and Embryonal × rolapitant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1 Neoplasms, Germ Cell and Embryonal 1 Nausea 1 Glioma 1

Interventions

Cisplatin 8 Etoposide 6 Paclitaxel 5 Ifosfamide 4 Sunitinib 3 Oxaliplatin 3 Cyclophosphamide 3 Brentuximab Vedotin 3 tremelimumab 2 pembrolizumab 2 etoposide phosphate 2 durvalumab 2 Sirolimus 2 Gemcitabine 2 Epirubicin 2 Dexamethasone 2 Carboplatin 2 Bleomycin 2 Bevacizumab 2 tozuleristide 1 rolapitant 1 ribociclib 1 pegfilgrastim 1 pazopanib 1 fosaprepitant 1 fludarabine phosphate 1 fludarabine 1 cabozantinib 1 avelumab 1 Teniposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡